Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $101,288.07 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $101,288.07. Following the completion of the transaction, the chief financial officer owned 43,741 shares of the company’s stock, valued at $4,207,446.79. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Eric Bjerkholt also recently made the following trade(s):

• On Thursday, January 22nd, Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $132,621.93.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $102.92 on Friday. The firm has a 50 day moving average of $79.65 and a 200-day moving average of $71.96. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $5.29 billion, a P/E ratio of -119.67 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $103.81.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm’s quarterly revenue was up 47.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) earnings per share. As a group, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on MIRM shares. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Citizens Jmp upped their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, December 19th. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $104.92.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Comerica Bank increased its stake in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. AQR Capital Management LLC increased its position in Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP purchased a new position in shares of Mirum Pharmaceuticals during the first quarter valued at about $217,000. Finally, Empowered Funds LLC raised its stake in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.